ES2530884T3 - Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10A - Google Patents
Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10A Download PDFInfo
- Publication number
- ES2530884T3 ES2530884T3 ES10760968T ES10760968T ES2530884T3 ES 2530884 T3 ES2530884 T3 ES 2530884T3 ES 10760968 T ES10760968 T ES 10760968T ES 10760968 T ES10760968 T ES 10760968T ES 2530884 T3 ES2530884 T3 ES 2530884T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- alkoxy
- fluoroalkyl
- hydroxy
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Compuestos de fórmula (I)**Fórmula** en los que A es N o C(R6); R1 es hidrógeno, alquilo inferior o fluoroalquilo inferior; R2 es halógeno, C(O)NR7R8 o C(O)OR9; R3 es hidrógeno, NR10R11, alquilo C1-7, alcoxi C1-7, fluoro-alquilo C1-7 o fluoro-alcoxi C1-7; R4 es hidrógeno, alquilo C1-7, fluoroalquilo C1-7, alcoxi C1-7 o fluoro-alcoxi C1-7; R5 es arilo o heteroarilo, que puede estar sustituido opcionalmente por 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en halógeno, alquilo C1-7, alcoxi C1-7, fluoroalquilo C1-7, fluoro-alcoxi C1-7 e hidroxi; R6 es hidrógeno, halógeno, CN, cicloalquilo, alquilo C1-7, cicloalquil-alquilo C1-7, alcoxi C1-7, fluoroalquilo C1-7 o fluoro-alcoxi C1-7; R7 y R8 independientemente el uno del otro se selecciona del grupo que consiste en hidrógeno, alquilo C1-7, alcoxi C1-7-alquilo C1-7, fluoroalquilo C1-7, cicloalquilo, cicloalquil-alquilo C1-7, NH2-alquilo C1-7, N(H,alquilo C1-7)-alquilo C1-C7, N(alquilo C1-7)2-alquilo C1-7, hidroxi-alquilo C1-7, hidroxi-alcoxi C1-7-alquilo C1-7, NH2C(O)-alquilo C1-7, N(H,alquilo C1-7)C(O)-alquilo C1-7, N(alquilo C1-7)2C(O)-alquilo C1-7, alcoxi C1-7, hidroxi-alquilo C1-7-oxetanil-alquilo C1-7, oxo-tetrahidrofuranilo, tetrahidrofuranil-alquilo C1-7, oxo-tetrahidrofuranil-alquilo C1-7, hidroxi-fluoroalquilo C1-7, tetrahidrofuranilo, arilo y heteroarilo, dicho arilo o heteroarilo pueden estar sustituidos opcionalmente por 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en halógeno, alquilo C1-7, alcoxi C1-7, fluoroalquilo C1-7, fluoro-alcoxi C1-7 e hidroxi, o R7 y R8, junto con el átomo de nitrógeno al que están unidos, forman un heterociclilo seleccionado de entre el grupo que consiste en pirrolidinilo, azetidinilo, morfolinilo, 5,6-dihidro-8-H- [1,2,4]triazolo [4,3-a]pirazinilo, 3,4-dihidro-1H-pirrolo[1,2-a]pirazinilo, 2-oxa-6-aza-spiro[3,3]heptilo, 5,6-dihidro-8H25 imidazo[1,2-a]pirazinilo, [1,4]oxazepanilo, piperazinilo, tiomorfolinilo y 2-oxa-5-aza-biciclo[2,2,1]heptilo, dicho heterociclilo puede estar sustituidos opcionalmente por 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en halógeno, alquilo C1-7, alquilo C1-7-C(O), alcoxi C1-7-alquilo C1-7, oxo, hidroxi, hidroxi-alquilo C1- 7, N(alquilo C1-7)2, NH2, N(H,alquilo C1-7), fluoroalquilo C1-7, fluoroalquilo C1-7-C(O), alcoxi C1-7 y fluoro-alcoxi C1-7; R9 es hidrógeno, alquilo C1-7, o fluoroalquilo C1-7; R10 y R11 independientemente el uno del otro son hidrógeno, alquilo C1-7 o fluoroalquilo C1-7, o R10 y R11, junto con el átomo de nitrógeno al que están unidos, forman un heterociclilo seleccionado de entre el grupo que consiste en piperidinilo, morfolinilo, pirrolidinilo, azetidinilo y piperazinilo, dicho heterociclilo puede estar sustituido opcionalmente por 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en halógeno, alquilo C1-7, alcoxi C1-7, fluoro-alquilo C1-7 y fluoro-alcoxi C1-7; y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09171253 | 2009-09-24 | ||
PCT/EP2010/063830 WO2011036127A1 (en) | 2009-09-24 | 2010-09-21 | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2530884T3 true ES2530884T3 (es) | 2015-03-06 |
Family
ID=43416552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10760968T Active ES2530884T3 (es) | 2009-09-24 | 2010-09-21 | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10A |
Country Status (22)
Country | Link |
---|---|
US (2) | US8017604B2 (es) |
EP (1) | EP2480546B1 (es) |
JP (1) | JP5629322B2 (es) |
KR (1) | KR101426624B1 (es) |
CN (1) | CN102548991B (es) |
AR (1) | AR078437A1 (es) |
BR (1) | BR112012006531A2 (es) |
CA (1) | CA2770087C (es) |
CL (1) | CL2012000708A1 (es) |
CY (1) | CY1116120T1 (es) |
DK (1) | DK2480546T3 (es) |
ES (1) | ES2530884T3 (es) |
HR (1) | HRP20150345T1 (es) |
IL (1) | IL218032A (es) |
MX (1) | MX2012003469A (es) |
PE (1) | PE20121438A1 (es) |
PL (1) | PL2480546T3 (es) |
PT (1) | PT2480546E (es) |
RU (1) | RU2502737C2 (es) |
SI (1) | SI2480546T1 (es) |
TW (1) | TWI402268B (es) |
WO (1) | WO2011036127A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8470820B2 (en) * | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
US9000186B2 (en) | 2011-02-01 | 2015-04-07 | Kyowa Hakko Kirin Co., Ltd. | Ring-fused heterocyclic derivative |
MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
US8975276B2 (en) * | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
EP2574607A1 (en) | 2011-09-06 | 2013-04-03 | F. Hoffmann-La Roche AG | PDE10 modulators |
ES2626801T3 (es) * | 2011-09-19 | 2017-07-26 | F. Hoffmann-La Roche Ag | Compuestos de triazolopiridina como inhibidores de pde10a |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
BR112015017674A2 (pt) * | 2013-01-31 | 2017-07-11 | Hoffmann La Roche | compostos rádio marcados |
CN106957317B (zh) * | 2013-02-27 | 2019-12-31 | 持田制药株式会社 | 新型吡唑衍生物 |
ES2624453T3 (es) * | 2013-04-29 | 2017-07-14 | F. Hoffmann-La Roche Ag | Derivados de 2-fenil o 2-hetaril-imidazol[1,2-a]piridina |
HUE032407T2 (en) * | 2013-04-30 | 2017-09-28 | Hoffmann La Roche | Plasma catalyzed coupling of pyrazolamides |
US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
WO2015044095A1 (en) * | 2013-09-26 | 2015-04-02 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pyridin-7-amines as imaging tools |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
PE20190607A1 (es) | 2016-09-02 | 2019-04-23 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
CN113698406A (zh) * | 2021-08-30 | 2021-11-26 | 成都药明康德新药开发有限公司 | 6-甲基吡唑并[1,5-a]嘧啶-3-胺的合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003513977A (ja) * | 1999-11-10 | 2003-04-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換2−アリール−3−(ヘテロアリール)−イミダゾ[1,2−α]ピリミジン類および関連薬剤組成物および方法 |
SE0102808D0 (sv) * | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
WO2004007471A1 (ja) * | 2002-07-12 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | N−フェニル−(2r,5s)ジメチルピペラジン誘導体 |
US20060106054A1 (en) | 2002-12-03 | 2006-05-18 | Michiaki Nagasawa | Phosphodiesterase 10a inhibitors |
US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
CN1950372A (zh) * | 2004-05-10 | 2007-04-18 | 万有制药株式会社 | 咪唑并吡啶化合物 |
CA2599987A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
CA2636112A1 (en) * | 2006-01-17 | 2007-07-26 | F.Hoffmann-La Roche Ag | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives useful for the treatment of alzheimer's disease via gaba receptors |
CA2643963A1 (en) * | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
DE102007012645A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
-
2010
- 2010-09-21 TW TW099132094A patent/TWI402268B/zh not_active IP Right Cessation
- 2010-09-21 PL PL10760968T patent/PL2480546T3/pl unknown
- 2010-09-21 CA CA2770087A patent/CA2770087C/en not_active Expired - Fee Related
- 2010-09-21 PE PE2012000365A patent/PE20121438A1/es not_active Application Discontinuation
- 2010-09-21 BR BR112012006531A patent/BR112012006531A2/pt not_active IP Right Cessation
- 2010-09-21 MX MX2012003469A patent/MX2012003469A/es active IP Right Grant
- 2010-09-21 EP EP10760968.7A patent/EP2480546B1/en not_active Not-in-force
- 2010-09-21 US US12/886,657 patent/US8017604B2/en not_active Expired - Fee Related
- 2010-09-21 CN CN201080042292.5A patent/CN102548991B/zh not_active Expired - Fee Related
- 2010-09-21 JP JP2012530234A patent/JP5629322B2/ja not_active Expired - Fee Related
- 2010-09-21 PT PT107609687T patent/PT2480546E/pt unknown
- 2010-09-21 SI SI201030869T patent/SI2480546T1/sl unknown
- 2010-09-21 ES ES10760968T patent/ES2530884T3/es active Active
- 2010-09-21 WO PCT/EP2010/063830 patent/WO2011036127A1/en active Application Filing
- 2010-09-21 KR KR1020127010422A patent/KR101426624B1/ko not_active IP Right Cessation
- 2010-09-21 RU RU2012113128/04A patent/RU2502737C2/ru not_active IP Right Cessation
- 2010-09-21 DK DK10760968.7T patent/DK2480546T3/en active
- 2010-09-23 AR ARP100103465A patent/AR078437A1/es not_active Application Discontinuation
-
2011
- 2011-06-02 US US13/151,310 patent/US8263584B2/en active Active
-
2012
- 2012-02-09 IL IL218032A patent/IL218032A/en not_active IP Right Cessation
- 2012-03-22 CL CL2012000708A patent/CL2012000708A1/es unknown
-
2015
- 2015-03-16 CY CY20151100263T patent/CY1116120T1/el unknown
- 2015-03-27 HR HRP20150345TT patent/HRP20150345T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PE20121438A1 (es) | 2012-10-26 |
MX2012003469A (es) | 2012-04-19 |
CN102548991A (zh) | 2012-07-04 |
TW201116530A (en) | 2011-05-16 |
AR078437A1 (es) | 2011-11-09 |
PL2480546T3 (pl) | 2015-05-29 |
JP5629322B2 (ja) | 2014-11-19 |
US20110071128A1 (en) | 2011-03-24 |
PT2480546E (pt) | 2015-02-09 |
SI2480546T1 (sl) | 2015-03-31 |
CA2770087A1 (en) | 2011-03-31 |
DK2480546T3 (en) | 2015-02-02 |
AU2010299927A1 (en) | 2012-03-15 |
WO2011036127A1 (en) | 2011-03-31 |
US8017604B2 (en) | 2011-09-13 |
TWI402268B (zh) | 2013-07-21 |
RU2012113128A (ru) | 2013-11-10 |
CL2012000708A1 (es) | 2012-09-07 |
CY1116120T1 (el) | 2017-02-08 |
CN102548991B (zh) | 2015-03-25 |
CA2770087C (en) | 2014-09-09 |
US8263584B2 (en) | 2012-09-11 |
HRP20150345T1 (hr) | 2015-05-08 |
EP2480546B1 (en) | 2014-12-31 |
EP2480546A1 (en) | 2012-08-01 |
US20110294779A1 (en) | 2011-12-01 |
RU2502737C2 (ru) | 2013-12-27 |
KR101426624B1 (ko) | 2014-08-05 |
KR20120068943A (ko) | 2012-06-27 |
JP2013505911A (ja) | 2013-02-21 |
IL218032A (en) | 2014-06-30 |
BR112012006531A2 (pt) | 2016-11-22 |
IL218032A0 (en) | 2012-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2530884T3 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10A | |
AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
AR066879A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
IL248466A (en) | Tricyclic compounds for drug preparation | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
DOP2014000055A (es) | Derivados de pirrolopirimidina y purina | |
CO2017003132A2 (es) | Inhibidores de la aldosterona sintasa derivados de la 2,6-diazaspiro[3.3]heptán-6-il]-3-piridil]isoindolín-1-ona o 2,7-diazaspiro[3.5]nonán-2-il]-3-piridil]isoindolín-1-ona | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
JP2017524702A (ja) | CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用 | |
PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
PE20121614A1 (es) | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 | |
PE20080067A1 (es) | DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR) | |
AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
PE20130234A1 (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
AR061058A1 (es) | Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas | |
AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 |